This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of formula I



I

in which

X denotes C ~~or N~~,

B denotes N, CH or C-CN,

R^1 denotes ~~H~~, A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^2 ~~if X = N~~

~~is absent or~~

~~if X = C~~

denotes ~~H, A, Hal~~, CN, ~~$-(CH_2)_p$-Ar,~~ ~~$-(CH_2)_p$-COOH, $-(CH_2)_p$-COOA, $-(CH_2)_p$-Het^3,~~ ~~$-(CH_2)_p$-NH_2, SO_2A, CHO or COA,~~

R^3 denotes H, A, -S-A, $-(CH_2)_p$-Ar, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Ar, NH-$(CH_2)_p$-Het, NH_2, NHA, NA_2, NH-alkylene-NH_2, NH-alkylene-NHA, NH-alkylene-NA_2 or NA-alkylene-NA_2,

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

R^5 denotes H or CH_3, or

R^4 and R^5 together denote Het^4—N(CH$_2$-CH$_2$-)(CH$_2$-CH$_2$-),

R^6 denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2$-COOH or $-OCH_2$-COOH,

Ar^1 denotes phenylene or piperazinediyl,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, OA, COOA, CN, $-(CH_2)_p$-Ar, $-(CH_2)_t$-OH, $-(CH_2)_p$-Het^1 or carbonyl oxygen (=O),

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Het^2 denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^3 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

m denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

~~and, if X = C,~~

~~R^1 and R^2 together may also denote $-(CH_2)_4-$ or~~

~~R^2 and R^3 together may also denote $-(CHR^7-CHR^8-NR^9-CHR^{10})-$,~~

and, if Ar^1 denotes piperazinediyl,

R^6 may also denote H or alkyl having 1-6 C atoms,

or a pharmaceutically acceptable ~~solvate,~~ tautomer, salt or stereoisomer thereof.

2. (Currently Amended) A compound according to Claim 1 in which

R^1 denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

m denotes 0.

3. (Previously Presented) A compound according to Claim 1 in which

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

s denotes 0 or 1,

n denotes 1,

Ar^1 denotes phenylene,

R^6 denotes Het^4,

Y denotes O,

Het^4 denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl.

4. (Previously Presented) A compound according to Claim 1 in which

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

s denotes 1,

n denotes 0,

Y denotes $(CH_2)_q$,

q denotes 0,

R^6 denotes Het^4,

Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A.

5. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 1, 2, 3 or 4.

6. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4.

7. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 1, 2, 3 or 4,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes Het^4,

Het^4	denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono-or disubstituted by A.

8. (Currently Amended) A compound according to Claim 1 in which

R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	~~if X = N is absent or~~ ~~if X = C denotes CN,~~
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het.

9. (Currently Amended) A compound according to Claim 1 in which

R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	~~if X = N is absent or~~ ~~if X = C denotes CN,~~
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
R^4	denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,
s	denotes 0,
n	denotes 0,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r$-NHA or $-(CH_2)_r-NA_2$,
r	denotes 1, 2, 3 or 4.

10. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n$-Y-R^6,
s	denotes 0,
n	denotes 1,

Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0.

11. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
q	denotes 0,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4.

12. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4.

13. (Currently Amended) A compound according to Claim 1 in which

R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	~~if X = N is absent or~~ ~~if X = C denotes~~ CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 0 or 1,
Y	denotes $(CH_2)_q$,
R^6	denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Ar^1	denotes phenylene,
Y	denotes O, $(CH_2)_q$ or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4.

14. (Currently Amended) A compound according to Claim 1 in which

R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	~~if X = N is absent or~~ ~~if X = C denotes~~ CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0,
n	denotes 1,
Ar^1	denotes phenylene,
R^6	denotes Het^4,
Y	denotes O,
Het^4	denotes pyridyl which is unsubstituted or monosubstituted by CONHA, or benzo-1,2,5-thiadiazol-5-yl.

15. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O or $(CH_2)_q$,

q	denotes 0,
R^6	denotes Het^4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
Ar^1	denotes phenylene.

16. (Previously Presented) A compound according to Claim 1 in which

Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,
Het^1	denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms,

or 

17. (Previously Presented) A compound according to Claim 1 in which

Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl

or 

18. (Previously Presented) A compound according to Claim 1 in which

R^4	denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s	denotes 0 or 1,
n	denotes 0 or 1,
Y	denotes O, $(CH_2)_q$ or NH,
Ar^1	denotes phenylene,
q	denotes 0, 1, 2, 3 or 4,
R^6	denotes Het^4, $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r	denotes 0, 1, 2, 3 or 4,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A or Ar^2,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A.

19. (Currently Amended) A compound according to Claim 1 in which

R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar,
m	denotes 0,
Ar	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R^2	~~if X = N~~ ~~is absent or~~ ~~if X = C~~ denotes CN,
R^3	denotes H, A, -S-A, phenyl or $-(CH_2)_p$-Het,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-,

di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,

Het^1 denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or 

20. (Previously Presented) A compound according to Claim 1 in which

R^4 denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

s denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

Y denotes O or $(CH_2)_q$,

Ar^1 denotes phenylene,

q denotes 0,

R^6 denotes Het^4, -$(CH_2)_r$-NH_2, -$(CH_2)_r$-NHA or -$(CH_2)_r$-NA_2,

r denotes 0, 1, 2, 3 or 4,

Het^4 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A.

21. (Previously Presented) A compound according to Claim 1 in which

Het^4 denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A or Ar^2.

22. (Previously Presented) A compound according to Claim 1 in which

R^4 denotes 4-(pyridin-4-yloxy)phenyl, 4-(pyridin-4-yloxy)-

phenylmethyl or 4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl, where the pyridine radical may be substituted by $CONHCH_3$.

23. (Previously Presented) A compound according to Claim 1 in which

Het^1 denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,

or 

24. (Previously Presented) A compound according to Claim 1 in which

Het^1 denotes morpholinyl, pyrrolidinyl, piperidinyl, pyridyl

or 

25. (Previously Presented) A compound according to Claim 1 in which

Het^2 denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms.

26. (Currently Amended) A compound according to Claim 1 in which

R^1 denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

R^2 ~~if X = N~~

~~is absent or~~

~~if X = C~~

denotes ~~H,~~ CN, ~~COOA or phenyl,~~

R^3 denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het,

NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or
NA-alkylene-NA_2.

27. (Currently Amended) A compound according to Claim 1 in which

R^2 ~~if X = N~~
~~is absent or~~
~~if X = C~~
denotes ~~H,~~ CN, ~~$(CH_2)_o$Ar", $(CH_2)_o$COOA or SO_2A,~~

Ar" denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o denotes 0 or 1.

28. (Currently Amended) A compound according to Claim 1 in which

R^1 denotes A, ~~OH, NH_2,~~ -$(CH_2)_m$-Ar' or -$(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl.

29. (Currently Amended) A compound according to Claim 1 in which

X denotes C ~~or N~~,

B denotes N, CH or C-CN,

R^1 denotes A, ~~OH, NH_2,~~ -$(CH_2)_m$-Ar' or -$(CH_2)_m$-Het^2,

Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,

m denotes 0,

Het^2 denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or pyridyl,

R^2 ~~if X = N~~
~~is absent or~~
~~if X = C~~
denotes ~~H,~~ CN, ~~$(CH_2)_o$Ar", $(CH_2)_o$COOA or SO_2A,~~

Ar" denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,

o	denotes 0 or 1,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, -$(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -$(CH_2)_t$-OH or -$(CH_2)_p$-Het^1,
Het^1	denotes morpholinyl, pyrrolidinyl, pyridyl
or	
R^4	denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,
Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3, or
R^4 and R^5	together denote  ,
R^6	denotes Het^4, -$(CH_2)_r$-NH_2, -$(CH_2)_r$-NHA or -$(CH_2)_r$-NA_2,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar^2,
Ar^1	denotes phenylene or piperazinediyl,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
R^7, R^8, R^9, R^{10}	each, independently of one another, denote H, A or -$(CH_2)_p$-Ar,
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,

r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,

~~and, if X = C,~~

~~R^1 and R^2 together may also denote $-(CH_2)_4-$ or~~

~~R^2 and R^3 together may also denote $-(CHR^7-NR^8-CHR^9-CHR^{10})-$,~~

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms.

30. (Currently Amended) A compound according to Claim 1 in which

X	denotes C ~~or N~~,
B	denotes N, CH or C-CN,
R^1	denotes A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar' or $-(CH_2)_m$-Het^2,
Ar'	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,
m	denotes 0,
Het^2	denotes an unsubstituted monocyclic aromatic heterocycle having 1-2 N, O and/or S atoms,
R^2	~~if X = N~~ ~~is absent or~~ ~~if X = C~~ denotes ~~H,~~ CN, ~~$(CH_2)_o$Ar'', $(CH_2)_o$COOA or SO_2A,~~
Ar''	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,
o	denotes 0 or 1,
R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Het, NA_2, NH-alkylene-NA_2 or NA-alkylene-NA_2,
Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA_2, COOA, benzyl, -

$(CH_2)_r$-OH or -$(CH_2)_p$-Het^1,

Het^1 denotes morpholinyl, pyrrolidinyl, pyridyl

or 

R^4 denotes -$(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

Y denotes O or $(CH_2)_q$,

R^5 denotes H or CH_3, or

R^4 and R^5 together denote  ,

R^6 denotes Het^4, -$(CH_2)_r$-NH_2, -$(CH_2)_r$-NHA or -$(CH_2)_r$-NA_2,

Het^4 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^1 denotes phenylene or piperazinediyl,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or -$(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

~~and, if X = C,~~

~~R^1 and R^2 together may also denote $-(CH_2)_4-$ or~~

~~R^2 and R^3 together may also denote $-(CHR^7-NR^8-CHR^9-CHR^{10})-$,~~

and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms.

31. (Cancelled)

32. (Cancelled)

33. (Currently Amended) A compound, whic h is

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,~~





~~(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,~~

~~(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,~~

~~7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,~~

~~5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,~~

~~7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,~~





~~6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,~~

















,



,



,



,



,




,


,


,


,


,













,



,



,



,



,



,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,

















;



,



,



, or









or a pharmaceutically acceptable ~~solvate,~~ tautomer, salt or stereoisomer thereof.

34. (Currently Amended) A process for preparing a compound according to Claim 1 or a pharmaceutically acceptable ~~solvate,~~ tautomer, salt or stereoisomer thereof, comprising

a) for the preparation of compounds of the formula I

in which X denotes C,

reacting a compound of formula II



II

,

in which R^4, R^5 and B have the meanings indicated for the compound of formula I,

i) with a compound of formula IIIa



IIIa

,

in which R^1 OA and R^2 and R^3 have the meanings indicated for the compound of formula I,

or

ii) with a compound of formula IIIb



IIIb

,

in which R^1, R^2 and R^3 have the meanings indicated for the compound of formula I,
and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

iii) with a compound of formula IIIc



IIIc

,

in which

R^1, besides the meanings indicated for the compound of formula I, also denotes OA,

R^2 and R^3 have the meanings indicated for the compound of formula I,

and A, A' each, independently of one another, denote alkyl having 1, 2, 3 or 4 C atoms,

or A and A' together form a butylene or pentylene chain,

~~or~~

~~b) for the preparation of compounds of the formula I in which X denotes N and R^1 denotes NH_2, reacting a compound of formula II with a compound of formula IIId~~



~~IIId~~

~~in which R^3 has the meaning indicated for the compound of formula I, and A denotes alkyl having 1, 2, 3 or 4 C atoms,~~

~~or~~

~~c) for the preparation of compounds of the formula I in which X denotes N,~~

~~R^1 denotes H, A, $(CH_2)_m$-Ar or $(CH_2)_m$-Het^2,~~

~~R^3 denotes S-A~~

~~reacting a compound of formula II with a compound of formula IIIe~~



~~IIIe~~

~~in which~~

~~R^1 denotes H, A, $(CH_2)_m$-Ar or $(CH_2)_m$-Het^2~~

~~and A denotes alkyl having 1, 2, 3 or 4 C atoms,~~

~~and/or one or more radical(s) R^1,R^2 and/or R^3 in a compound of formula I is (are) converted into one or more other radical(s) R^1,R^2 and/or R^3,~~

and/or

a base or acid of a compound of formula I is converted into one of its salts.

35. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

36-57. (Cancelled)

58. (Previously Presented) A process according to claim 34, wherein one or more radical(s) R^1,R^2 and/or R^3 in a compound of formula I is (are) converted into one or more other radical(s) R^1,R^2 and/or R^3, by

i) converting an alkylsulfanyl group into an amine,

ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol, or

iii) reducing a nitrile to the aldehyde or amine.

59. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 33 and a pharmaceutically acceptable carrier.

60. (Currently Amended) A compound of formula I according to claim 1,

in which

X denotes C ~~or N~~,

B denotes N, CH or C-CN,

R^1 denotes ~~H~~, A, ~~OH, NH_2,~~ $-(CH_2)_m$-Ar or $-(CH_2)_m$-Het^2,

R^2 ~~if X = N~~

~~is absent or~~

~~if X = C~~

denotes ~~H, A, Hal~~, CN, ~~$-(CH_2)_p$-Ar,~~ ~~$-(CH_2)_p$-COOH, $-(CH_2)_p$-COOA, $-(CH_2)_p$-Het^3,~~ ~~$-(CH_2)_p$-NH_2, SO_2A, CHO or COA,~~

R^3 denotes H, A, -S-A, $-(CH_2)_p$-Ar, $-(CH_2)_p$-Het, NH-$(CH_2)_p$-Ar, NH-$(CH_2)_p$-Het, NH_2, NHA, NA_2, NH-alkylene-NH_2, NH-alkylene-NHA, NH-alkylene-NA_2 or NA-alkylene-NA_2,

R^4 denotes $-(CH_2)_s$-$(Ar^1)_n$-Y-R^6,

R^5 denotes H or CH_3, or

R^4 and R^5 together denote Het^4—N(-CH_2-CH_2-)(-CH_2-CH_2-),

R^6 denotes Het^4, $-(CH_2)_r$-NH_2, $-(CH_2)_r$-NHA or $-(CH_2)_r$-NA_2,

Y denotes O, S, $(CH_2)_q$ or NH,

Ar denotes phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2, SO_2A, $-CH_2$-COOH or $-OCH_2$-COOH,

Ar^1 denotes phenylene or piperazinediyl,

Het denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA,

NA_2, OA, COOA, CN, $-(CH_2)_p$-Ar, $-(CH_2)_t$-OH, $-(CH_2)_p$-Het^1 or carbonyl oxygen (=O),

Het^1 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),

Het^2 denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^3 denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,

Het^4 denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, $CONH_2$, CONHA, $CONA_2$ or Ar^2,

Ar^2 denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2, NO_2, CN, COOH, COOA, $CONH_2$, NHCOA, $NHCONH_2$, $NHSO_2A$, CHO, COA, SO_2NH_2 or SO_2A,

R^7, R^8, R^9, R^{10} each, independently of one another, denote H, A or $-(CH_2)_p$-Ar,

A denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,

m denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

p denotes 0, 1, 2, 3 or 4,

q denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

~~and, if X = C,~~

~~R^1 and R^2 together may also denote $-(CH_2)_4$- or~~

~~R^2 and R^3 together may also denote $-(CHR^7-CHR^8-NR^9-CHR^{10})-$,~~

and, if Ar^1 denotes piperazinediyl,

R^6 may also denote H or alkyl having 1-6 C atoms,

or a pharmaceutically acceptable salt thereof.

61. (Previously Presented) A pharmaceutical composition comprising a compound according to claim 60 and a pharmaceutically acceptable carrier.

62. (Currently Amended) A compound according to claim 33, which is

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,~~





~~(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methyl-aminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,~~

~~(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,~~

~~(2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,~~

~~(3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,~~

~~7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazool[1,5-a]pyrimidine-3-carbonitrile,~~

~~7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,~~

~~5,7-dimethyl-2-[4-(pyridin-4-yloxy)phenylamino]pyrazolo[1,5-a]-pyrimidine-3-carbonitrile,~~

~~7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,~~





~~6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaazacyclopenta[b]naphthalen-4-ol,~~

















,



,



,



,



,




,


,


,


,


,



,



,



,



,



,



,



,



,



,



,



,


,


,


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,



,



,



,



,



,







;



,



,



, or









or a pharmaceutically acceptable salt thereof.

63. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 62 ~~61~~ and a pharmaceutically acceptable carrier.

64. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier ~~compound according to claim 1 in which X denotes C~~.

65. (Cancelled)

66. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 29 and a pharmaceutically acceptable carrier ~~compound according to claim 60 in which X denotes C~~.

67. (Cancelled)

68. (Currently Amended) A pharmaceutical composition comprising a compound according to claim 30 ~~66~~ and a pharmaceutically acceptable carrier.

69. (Cancelled)

70. (New) A compound according to Claim 1, in which R^1 denotes A.

71. (New) A compound according to Claim 1, in which R^1 denotes $-(CH_2)_m$-Ar.

72. (New) A compound according to Claim 1, in which R^1 denotes $-(CH_2)_m$-Het^2.

73. (New) A compound according to Claim 1, in which B denotes N.

74. (New) A compound according to Claim 1, in which B denotes C-CN.